Company Overview and News

76
Top 7 5G Stocks To Play The 5G Boom Starting In 2019

2018-10-12 seekingalpha - 5
This article first appeared on Trend Investing on Aug. 14, 2018; therefore all data is as of that date.
MOMO NFLX HPE VZA SWKS AAPL CSCO NOK INTC CSCOI CHLKF VOD VOD HXSCF BC94 SMSN 0941 S CHL VODPF GOOGL MU VZ MSFT QCOM HXSCL SMSD

40
Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Conagra, Facebook, GE, Halliburton, Petrobras, Schlumberger, Vodafone, Walmart and More

2018-10-08 247wallst - 1
Stocks were looking to open lower on Monday, but it was expected to be a fairly quiet day with the Columbus Day holiday keeping part of the banking system closed. U.S. equity indexes are just under all-time highs, but investors have been seeing lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how they want to position their investments for the rest of 2018 and into 2019.
HAL FB ABT WMT HUN AAPL CAG TMHC ABT SLB EA GE GEC VOD VOD CBT BHGE KMB PBR MDT BHI BLK VODPF TRI GNE SCL SLB

7
Market Snapshot: Dow hits record, aims for fifth straight advance as Italy fears fade

2018-10-03 marketwatch
U.S. stocks rose on Wednesday, with the Dow Jones Industrial Average hitting its latest in a series of records and aiming for a fifth straight positive session.
FB VOD ADPVV VOD VODPF ADP TPX DTK RPM

3
‘Serious’ query from Vodafone about 3rd player auction — Diokno

2018-10-03 bworldonline - 1
THE UK’s Vodafone Group PLC has discussed with the government the possibility of participating in the selection process for the telecommunications industry’s so-called “third player,” Budget Secretary Benjamin E. Diokno said following a visit to London.
K3ED VOD CHJHF VOD VODPF NOW KT CHA 0728 ECP DNOW

158
Snap, Rite Aid Wallow in Tuesday’s 52-Week Low Club

2018-10-02 247wallst
October 2, 2018: Here are four stocks trading with heavy volume among 173 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 1.83 to 1, and on the Nasdaq, decliners led advancers by about 2.08 to 1.
VOD VOD VODPF RAD LYG SNAP

1
Axiata’s Asia dream fades as rivals bid for its overseas units

2018-10-02 theedgemarkets
SINGAPORE (Oct 2): Axiata Group Bhd’s dream of building a carrier that spans southern Asia from Singapore to Pakistan, Indonesia and India is fading as it risks losing hold of overseas units to rivals.
SGPRY VOD VOD VODPF 6888 SGPRF IDEA ICLQY AXXTF 532822

24
47 Nasdaq 'Safer' Dividend Dogs For September 2019

2018-09-28 seekingalpha - 1
47 of 53 NASDAQ-100 Index dividends were presumed "safer" because they showed positive one-year returns and free cash flow yields greater than dividend yields as of 9/25/18.
LRCX VOD VOD GILD CMCSA WDC STX MCHP KLAC SWKS PEP VODPF AVGO QCOM INTC MXIM PAYX

1
Vodafone Selects Juniper Networks as an Enterprise Global SD-WAN Partner

2018-09-25 globenewswire
SUNNYVALE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, today announced that Vodafone has selected the company as one of its Software-Defined Wide Area Network (SD-WAN) vendors for its enterprise-focused SDN portfolio, referred to as ‘Ready Network.’ Vodafone’s portfolio will comprise flexible, cloud-based services that are designed to underpin digital business at scale, helping enterprises to compete effectively using agile, open and fast infrastructure with zero-touch deployment.
VOD VOD VODPF JNPR

4
Sanchez Midstream Tagged 'Safer' Dividend Follower Favorite Per Stockbroker September Surveys

2018-09-20 seekingalpha
From 8/15/18-9/17/18, Fredrik Arnold dividend "followers" commented on 40 equities and funds. Some comments were bad news, so some rogues mixed in to create a FollowerFavorite/Rogue (FoFa/Ro) list.
KWH.UN VOD VOD SXCP CRIUF ORC DVDDF CHMI CZZ CJREF CIM GMLP VODPF CJR.B CVX AVGO BRCM INTC SNMP

16
Fredrik Followers Favored 40 As Most Mentioned September Equities And Funds

2018-09-20 seekingalpha
August 15-September 17, Fredrik Arnold "followers" mentioned 40 equities & funds in their comments and suggestions. Some lamented bad news, so bad news investments mixed in with their favorites.
ARLP GIS AMID KWH.UN VOD VOD CRIUF ORC CNSL TYG CJREF CIM GMLP VODPF CJR.B CBL SNMP

16
Fredrik Followers Favored 40 As Most Mentioned September Equities & Funds

2018-09-20 seekingalpha
August 15-September 17, Fredrik Arnold "followers" mentioned 40 equities & funds in their comments and suggestions. Some lamented bad news, so bad news investments mixed in with their favorites.
ARLP GIS AMID KWH.UN VOD VOD CRIUF ORC CNSL TYG CJREF CIM GMLP VODPF CJR.B CBL SNMP

1
Acquisitive Indian billionaire says he's hungry for deals

2018-09-19 theedgemarkets
(Sept 19): Kumar Mangalam Birla, the billionaire chairman of the acquisitive Indian conglomerate that bears his name, said he’s hungry for more deals after creating the nation’s biggest mobile-phone operator.
HINDALCO VOD VOD 532538 UCLQF ICLQY ALSD 532822 ULTRACEMCO HNDNF VODPF UCLQY IDEA 500440

1
Kumar Mangalam Birla says he is hungry for more deals

2018-09-19 livemint
Mumbai: Kumar Mangalam Birla, the billionaire chairman of the acquisitive Indian conglomerate that bears his name, said he’s hungry for more deals after creating the nation’s biggest mobile-phone operator. His Aditya Birla Group continues to look for targets in the US, Europe and India that make business sense and are likely to add value, the 51-year-old said at Bloomberg’s India Economic Forum on 18 September in Mumbai.
HINDALCO VOD VOD 532538 UCLQF ICLQY ALSD 532822 ULTRACEMCO HNDNF VODPF UCLQY IDEA 500440

1
Vodafone NZ float on the cards for 2019 - FT report

2018-09-17 nzherald.co.nz
Vodafone Group's incoming chief executive Nick Read says a float of the New Zealand unit is on the cards next year.
SKT SYKWF VOD VOD VODPF NZTCY SPKKY SKKTY SPK NZTCF

17
PRESS DIGEST- British Business - Sept 13

2018-09-13 reuters
Sept 13 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
FB LLOY VOD VOD LYG GOOG LLPH LLPK LLPJ LLPE LLPD LLOBF VODPF GOOGL LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 92857W100